
Robbie Marcus
Stock Analyst at J.P. Morgan
(4.51)
# 1,096
Out of 5,184 analysts
557
Total ratings
53.2%
Success rate
8.3%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HTFL HeartFlow | Maintained: Buy | $45 → $60 | $56.66 | +5.89% | 7 | Nov 17, 2026 | |
| ENOV Enovis | Maintained: Hold | $28 → $27 | $28.54 | -5.40% | 7 | Nov 10, 2026 | |
| BDX Becton, Dickinson and Company | Rated: Hold | $188 → $220 | $215.25 | +2.21% | 15 | Nov 6, 2026 | |
| CBLL CeriBell | Reiterated: Buy | $17 → $31 | $27.60 | +12.32% | 6 | Nov 5, 2026 | |
| EW Edwards Lifesciences | Reiterated: Buy | $105 → $120 | $104.71 | +14.60% | 26 | Nov 5, 2026 | |
| PODD Insulet | Reiterated: Hold | $152 → $170 | $149.81 | +13.48% | 27 | Nov 5, 2026 | |
| ZBH Zimmer Biomet Holdings | Reiterated: Hold | $117 → $120 | $108.33 | +10.77% | 19 | Nov 5, 2026 | |
| INSP Inspire Medical Systems | Rated: Hold | $60 → $65 | $64.33 | +1.04% | 22 | Nov 3, 2026 | |
| BSX Boston Scientific | Reiterated: Hold | n/a | $44.02 | - | 31 | Nov 2, 2026 | |
| BAX Baxter International | Reiterated: Hold | $26 → $25 | $26.41 | -5.34% | 25 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $82 → $85 | $81.07 | +4.85% | 28 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $95 → $110 | $88.42 | +24.41% | 7 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $350 → $340 | $325.73 | +4.38% | 20 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $16 → $22 | $20.96 | +4.96% | 14 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 → $50 | $51.94 | -3.74% | 21 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $70 → $80 | $84.03 | -4.80% | 6 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $118 | $110.51 | +6.78% | 20 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $17 → $14 | $14.37 | -2.57% | 22 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $450 → $475 | $460.56 | +3.14% | 21 | Oct 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $102.79 | - | 28 | Oct 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $71 → $58 | $63.93 | -9.28% | 21 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $17 | $12.26 | +38.66% | 2 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $30.12 | -0.40% | 1 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $9 → $6 | $4.86 | +23.46% | 19 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $6 | $0.7806 | +668.64% | 16 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $275 → $370 | $321.85 | +14.96% | 25 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $9 → $7 | $6.12 | n/a | 27 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $13 → $7 | $11.02 | n/a | 8 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $51 | $57.78 | n/a | 20 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 → $14 | $13.12 | n/a | 10 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $8 | $4.78 | n/a | 7 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $80 → $85 | $238.74 | n/a | 13 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $95 | $88.73 | n/a | 14 | Apr 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $93.79 | n/a | 1 | May 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $40 | $18.54 | n/a | 1 | Jun 8, 2018 |
HeartFlow
Nov 17, 2026
Maintained: Buy
Price Target: $45 → $60
Current: $56.66
Upside: +5.89%
Enovis
Nov 10, 2026
Maintained: Hold
Price Target: $28 → $27
Current: $28.54
Upside: -5.40%
Becton, Dickinson and Company
Nov 6, 2026
Rated: Hold
Price Target: $188 → $220
Current: $215.25
Upside: +2.21%
CeriBell
Nov 5, 2026
Reiterated: Buy
Price Target: $17 → $31
Current: $27.60
Upside: +12.32%
Edwards Lifesciences
Nov 5, 2026
Reiterated: Buy
Price Target: $105 → $120
Current: $104.71
Upside: +14.60%
Insulet
Nov 5, 2026
Reiterated: Hold
Price Target: $152 → $170
Current: $149.81
Upside: +13.48%
Zimmer Biomet Holdings
Nov 5, 2026
Reiterated: Hold
Price Target: $117 → $120
Current: $108.33
Upside: +10.77%
Inspire Medical Systems
Nov 3, 2026
Rated: Hold
Price Target: $60 → $65
Current: $64.33
Upside: +1.04%
Boston Scientific
Nov 2, 2026
Reiterated: Hold
Price Target: n/a
Current: $44.02
Upside: -
Baxter International
Oct 30, 2026
Reiterated: Hold
Price Target: $26 → $25
Current: $26.41
Upside: -5.34%
Oct 30, 2026
Rated: Hold
Price Target: $82 → $85
Current: $81.07
Upside: +4.85%
Oct 30, 2026
Rated: Buy
Price Target: $95 → $110
Current: $88.42
Upside: +24.41%
Oct 30, 2026
Reiterated: Buy
Price Target: $350 → $340
Current: $325.73
Upside: +4.38%
Oct 29, 2026
Reiterated: Hold
Price Target: $16 → $22
Current: $20.96
Upside: +4.96%
Oct 29, 2026
Reiterated: Hold
Price Target: $45 → $50
Current: $51.94
Upside: -3.74%
Oct 29, 2026
Reiterated: Hold
Price Target: $70 → $80
Current: $84.03
Upside: -4.80%
Oct 22, 2026
Reiterated: Buy
Price Target: $118
Current: $110.51
Upside: +6.78%
Oct 22, 2026
Reiterated: Sell
Price Target: $17 → $14
Current: $14.37
Upside: -2.57%
Oct 21, 2026
Rated: Buy
Price Target: $450 → $475
Current: $460.56
Upside: +3.14%
Oct 16, 2026
Reiterated: Hold
Price Target: n/a
Current: $102.79
Upside: -
Sep 10, 2026
Rated: Hold
Price Target: $71 → $58
Current: $63.93
Upside: -9.28%
Aug 12, 2026
Reiterated: Buy
Price Target: $15 → $17
Current: $12.26
Upside: +38.66%
Aug 10, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $30.12
Upside: -0.40%
Aug 6, 2026
Reiterated: Sell
Price Target: $9 → $6
Current: $4.86
Upside: +23.46%
May 12, 2026
Reiterated: Sell
Price Target: $6
Current: $0.7806
Upside: +668.64%
Dec 18, 2025
Upgraded: Buy
Price Target: $275 → $370
Current: $321.85
Upside: +14.96%
Aug 8, 2025
Reiterated: Sell
Price Target: $9 → $7
Current: $6.12
Upside: n/a
May 6, 2025
Reiterated: Hold
Price Target: $13 → $7
Current: $11.02
Upside: n/a
Feb 11, 2025
Reiterated: Buy
Price Target: $40 → $51
Current: $57.78
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $9 → $14
Current: $13.12
Upside: n/a
May 8, 2024
Downgraded: Hold
Price Target: $15 → $8
Current: $4.78
Upside: n/a
May 6, 2021
Reiterated: Sell
Price Target: $80 → $85
Current: $238.74
Upside: n/a
Apr 12, 2021
Downgraded: Hold
Price Target: $95
Current: $88.73
Upside: n/a
May 28, 2019
Initiated Coverage: Buy
Price Target: $34
Current: $93.79
Upside: n/a
Jun 8, 2018
Upgraded: Buy
Price Target: $40
Current: $18.54
Upside: n/a